Table 2.
Illustration of routine CSF parameters in SMA patients undergoing treatment with nusinersen.
| White cells (count/μL) | Total protein (mg/L) | Qalb (×103) | Lactate (mmol/L) | OCB | |
|---|---|---|---|---|---|
| T1 | 1.0 [0.0;1.8] range 0.0–4.0 N = 60 |
319.5 [246.8;421.0] range 148.0–715.0 N = 60 |
4.20 [3.45; 6.35] range 2.20–11.40 N = 57 |
1.40 [1.30;1.60] range 0.90–2.80 N = 60 |
Positive in CSF (type 2/3): 2 N = 51 |
| T2 | 1.0 [1.0; 2.0] range 0.0–4.0 N = 59 |
343.0 [268.0; 422.0] range 153.0–1300.0 N = 59 |
4.70 [3.73; 6.40] range 2.30–15.60 N = 56 |
1.40 [1.25; 1.61] range 1.00–2.80 N = 58 |
Positive in CSF (type 2/3): 2 N = 51 |
| T3 | 1.0 [0.0; 2.0] range 0.0–8.0 N = 58 |
339.0 [275.5; 449.3] range 139.0–1110.0 N = 56 |
4.57 [3.80; 6.55] range 2.19–14.34 N = 51 |
1.44 [1.30; 1.60] range 1.08–3.05 N = 57 |
Positive in CSF (type 2/3): 3 N = 52 |
| T4 | 1.0 [0.0; 1.0] range 0.0–4.0 N = 58 |
318.0 [268.3; 437.3] range 178.0–1040.0 N = 56 |
4.70 [3.68; 6.94] range 2.60–15.00 N = 50 |
1.40 [1.23; 1.60] range 1.03–2.80 N = 57 |
Positive in CSF (type 2/3): 2 N = 49 |
| T5 | 1.0 [0.0; 2.0] range 0.0–4.0 N = 46 |
352.0 [280.8; 439.0] range 184.0–809.0 N = 46 |
4.70 [3.75; 6.16] range 2.14–11.20 N = 45 |
1.50 [1.27; 1.70] range 1.00–3.00 N = 45 |
Positive in CSF (type 2/3): 2 N = 43 |
| T6 | 1.0 [0.5; 2.0] range 0.0–3.0 N = 37 |
347.0 [292.5; 464.5] range 175.0–809.0 N = 37 |
4.90 [3.88; 6.37] range 2.42–13.14 N = 37 |
1.45 [1.23; 1.70] range 1.00–3.10 N = 37 |
Positive in CSF (type 2/3): 1 N = 37 |
| T7 | 1.0 [1.0; 1.0] range 0.0–3.0 N = 25 |
355.0 [302.0; 438.5] range 172.0–838.0 N = 25 |
5.00 [3.85; 6.63] range 2.39–12.48 N = 25 |
1.40 [1.21; 1.70] range 1.07–2.30 N = 25 |
Positive in CSF: type 2/3: 0 N = 25 |
| T8 | 1.0 [1.0; 2.0] range 0.0–4.0 N = 9 |
322.0 [282.0; 433.5] range 218.0–592.0 N = 9 |
4.15 [3.65; 6.83] range 3.50–7.81 N = 8 |
1.30 [1.20; 1.57] range 1.13–1.90 N = 9 |
Positive in CSF: type 2/3: 0 N = 5 |
Median values with quartiles (in square brackets) and ranges of white cell count, total protein, and lactate in CSF and of Qalb at treatment days T1–T8 are shown; number of samples with positive IgG bands in CSF (OCB type 2 and 3) at treatment days T1–T8 is presented. Qalb, albumin CSF/serum quotient; OCB, oligoclonal IgG bands; N, number of available samples.